MRX-800: A Long-Term Safety Study of Maralixibat in the Treatment of Cholestatic Liver Disease in Subjects Who Previously Participated in a Maralixibat Study
NCT04168385
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
52
Enrollment
INDUSTRY
Sponsor class
Conditions
Cholestatic Liver Disease
Interventions
DRUG:
Maralixibat
Sponsor
Mirum Pharmaceuticals, Inc.